Another Potential Food Allergy Treatment is Snapped Up by Big Pharma

Big Pharma’s growing interest in food allergy treatments is increasingly showing up in its acquisition strategy, as major drugmakers look to smaller biotechnology companies for promising new approaches to allergic disease. In the latest example, Eli Lilly announced it is acquiring Merida Biosciences in a deal worth up to $2.875 billion. Although Merida is developing treatments across autoimmune and allergic diseases, its pipeline includes a potentially important food allergy candidate, adding to a broader trend of large pharmaceutical companies acquiring or partnering with smaller biopharmas developing next-generation allergy treatments.

Of particular interest to the food allergy community is MER769, a preclinical therapy designed to target Immunoglobulin E, or IgE, the antibody responsible for triggering allergic reactions to food that affect roughly 1 in 10 adults in the United States, according to Merida. For millions, accidental exposure can cause symptoms ranging from hives and vomiting to life-threatening anaphylaxis. Avoidance and ready access to epinephrine remain cornerstones of food allergy management, although newer therapies, including oral immunotherapy and the anti-IgE drug Xolair (omalizumab), can provide additional protection for some patients.

MER769 aims to take the anti-IgE strategy considerably further. Currently undergoing studies intended to support its advancement into human clinical trials, the experimental therapy is designed not merely to neutralize IgE but to eliminate it and inhibit its continued production. Merida says the approach has the potential to address higher IgE levels than current therapies while allowing less frequent dosing, reducing toxicity, and providing greater clinical benefit. The company is also developing MER769 for other IgE-driven conditions, including asthma and chronic spontaneous urticaria. Those potential advantages remain to be demonstrated in clinical trials.

For Lilly, the acquisition provides access to technology designed to attack the biological drivers of immune-mediated disease rather than broadly suppressing immune activity. “We’re building our pipeline around therapies that meaningfully change the course of disease, not just its downstream effects,” said Francisco Ramírez-Valle, MD, PhD, senior vice president of Lilly immunology research and early clinical development. “We see potential to apply this precision approach across a broad range of antibody-driven diseases, and we look forward to advancing this novel technology working with the Merida team.”

The deal also illustrates an increasingly important dynamic in the search for better food allergy treatments: promising science often begins at relatively small biotechnology companies, while the enormous resources needed to conduct large clinical trials, navigate regulatory approval, and ultimately commercialize a therapy can make those companies attractive acquisition or partnership targets for pharmaceutical giants. “Merida was founded to fundamentally change how autoimmune and allergic diseases are treated, by targeting the antibodies driving them directly, rather than suppressing the immune system broadly,” said Adam Townsend, chief executive officer of Merida. Townsend added that “joining Lilly gives our science the resources and commitment to realize its potential for patients with immune-mediated conditions.”

Merida’s approach is designed to work like a highly targeted biological cleanup system. Rather than broadly suppressing immune function, its technology targets specific disease-driving antibodies for removal while seeking to preserve normal immune defenses. In the case of MER769, the target is IgE, the antibody at the heart of immediate allergic reactions. If the approach proves safe and effective in humans, eliminating IgE and inhibiting its replenishment could potentially provide another way of protecting patients from reactions to accidental food exposures. But MER769 remains preclinical, meaning its safety, effectiveness, dosing requirements, and advantages over existing treatments have yet to be established in patients.

Merida is also not an isolated example of why food allergy biotechnology has attracted the attention of larger pharmaceutical companies. As researchers uncover new ways to interfere with IgE, mast cells and other components of the allergic response, potentially valuable therapies are emerging from smaller biopharmas that may eventually be acquired, licensed, or partnered with companies possessing the resources to bring them through late-stage development. Lilly’s acquisition of Merida therefore represents more than a single experimental food allergy drug: it is another indication that promising allergy science has become strategically valuable to the world’s largest drugmakers.

The acquisition, which is expected to close in the fourth quarter of 2026 subject to customary conditions and regulatory approvals, could ultimately be worth $2.875 billion, including an upfront payment and milestone-based consideration. That valuation encompasses Merida’s entire technology platform and pipeline—not MER769 or food allergy alone. Still, for the food allergy community, the significance is difficult to overlook: one of the world’s largest pharmaceutical companies is committing billions to acquire a small biotech whose pipeline includes a fundamentally different approach to targeting IgE. As more promising food allergy therapies emerge from biotechnology startups, the race among Big Pharma to acquire, license, and develop that science may prove almost as consequential as the scientific race itself.